{{header
 | author     = Robert Hurt (politician)
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 12
 | day        = 02
 | notes      = ''{{USBill|113|H.R.|3631}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Small Manufacturer Protection Act of 2013 ( H.R. 3631; 113th Congress)
 | bill       = 3631
 | billtype   = hr
 | purpose    = To authorize the Commissioner of Food and Drugs to waive or reduce certain fees applicable to generic drug facilities where the fees would present a significant barrier to market entry because of limited resources available to such facilities or other circumstances.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|1st Session}}

 
{{Center|H. R. 3631}}

 
{{Center|IN THE HOUSE OF REPRESENTATIVES}}

  
{{Center|December 2, 2013}}

 
{{Center| 
[[w:Robert Hurt (politician)|Mr. Hurt]](for himself and
[[w:Phil Roe (politician)|Mr. Roe of Tennessee]]) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]] }}

  
{{Center|A BILL}}

 To authorize the Commissioner of Food and Drugs to waive or reduce certain fees applicable to generic drug facilities where the fees would present a significant barrier to market entry because of limited resources available to such facilities or other circumstances.   

=Section 1. Short title=

This Act may be cited as the“ Small Manufacturer Protection Act of 2013 ”. 

=Sec. 2. Waiver or reduction of certain fees applicable to generic drug facilities=



==(a) In general– ==

   Section 744B of the Federal Food, Drug, and Cosmetic Act ( [http://www.law.cornell.edu/uscode/text/21/379j–42 21 U.S.C. 379j–42] )is amended—
:(1) in subsection (b)(1)(B) , by inserting“, except as provided in subsection (c)(3) ,”after“fees under paragraphs (2) through (4) of subsection (a) shall”; and
:(2) in subsection (c) , by adding at the end the following:

<blockquote> 

====(3) Fee waivers– ====



=====(A) Standard– =====

The [[w:Department of Health and Human Services|Secretary]]shall grant to a person that owns a generic drug facility a waiver from or a reduction of one or more fees assessed to that person under subsection (a) where the [[w:Department of Health and Human Services|Secretary]]finds that the assessment of the fee would present a significant barrier to market entry because of limited resources available to such person or other circumstances.

=====(B) Considerations– =====

In determining whether to grant a waiver or reduction of a fee under subparagraph (A) , the [[w:Department of Health and Human Services|Secretary]]shall consider only the circumstances and assets of the person involved and any affiliate of the person.

=====(C) Written requests– =====

To qualify for consideration for a waiver or reduction under subparagraph (A) , a person shall submit to the [[w:Department of Health and Human Services|Secretary]]a written request for such waiver or reduction not later than 180 days after the fee is due.

=====(D) Definition– =====

In this paragraph, the term person that owns a generic drug facility means a person that owns a facility which is identified or intended to be identified in at least one generic drug submission that is pending or approved to produce one or more finished dosage forms of a human generic drug. . 
</blockquote>


==(b) Applicability– ==

The amendments made by this section apply with respect to fees authorized to be assessed and collected for any of fiscal years 2014 through 2017.  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
